Global Contract Manufacturing of Pharmaceuticals

Dybendal Alle 10,
2630 Taastrup,

Research-based company focusing on pharmaceuticals

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine.

Takeda’s ethical drugs are marketed in around 100 countries worldwide.

The network of the Takeda group spans across 70 countries and regions worldwide, in Japan, the US, Europe, Russia and CIS, Latin America, Africa, the Middle East, and the Asia-Pacific region.

Pharmaceutical contract manufacturing

Takeda manufactures products for a substantial number of external clients ranging from global to regional to local companies. Takeda delivers services to its customers with the right balance of quality, reliability, responsiveness and costs.

As a testimony to Takeda’s high customer focus, Takeda was in 2013 awarded with the CMO awards within reliability and quality.

Kim Wochner, from the contract manufacturing business, said: “Takeda is very proud of receiving this award within the areas of quality and reliability. We believe that this is key to success within contract manufacturing.

“Our consistent focus over the years in building quality in everything we do has with this award been recognised by our clients and industry. Many years within pharmaceutical production and long-lasting partnerships have demonstrated the reliability in our services. Thank you all for this award.”

Our success is based on a customer-tailored approach and quality standards aligned with regulatory authorities in the US, Europe, Japan, South and Central America, and other regions.

Optimised pharma manufacturing services

Partnership plays a vital role for all of our operational activities. Close cross-functional collaboration and seamless processes between internal teams and external partners help us to respond quickly and accurately to market demand.

Our manufacturing operations provide a competitive advantage through an innovative, global supply chain network. This network is constantly reviewed and optimized in the interests of increasing the use of its capacity, enhancing supply chain performance, maintaining a high level of customer service and decreasing the cost of goods sold.

Our 19 manufacturing facilities located in twelve countries meet the highest international quality standards and are inspected by all the major health authorities. Our combination of central and regional manufacturing acts to ensure rapid response when opening up new and expanding existing markets.

Solids, semi-solids, liquids and sterile production

We offer a wide range of technologies: production and packaging of solid, semi-solid and liquid pharmaceuticals, as well as sterile and non-sterile manufacturing.

Our technologies produce all classic pharmaceutical dosage forms such as:

  • Solids (tablets, capsules, powders and pellets)
  • Liquids (suspensions, syrups and solutions)
  • Sterile liquids (ear, eye and nasal drops)

Wallet packaging, sachets, bottles, ampoules, blisters and vials

Takeda provides the whole range of packaging technologies for solids, semi-solids and liquids, sterile and non-sterile products:

  • Blisters in various formats (PVC, PVC/PVDC, PVC/Alu, Alu/Alu, Aclar, Triplex, COC)
  • Bottles (glass, PE)
  • Sachets (Alu/Alu)
  • Stick packs
  • Wallet packaging
  • Thermo-shaped units
  • Tubes (Alu)
  • Ampoules (glass, plastic)
  • Flaconettes (glass, plastic)
  • Pre-filled syringes (glass, plastic)
  • Vials (glass, plastic)
  • Blow-fill-seal (gels, liquids)
  • Pump sprays

AXELEAD Begins Operations

Takeda Pharmaceutical Company and Axcelead Drug Discovery Partners has announced the start of operations for AXCELEAD.

Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn’s Disease in the EU

Takeda Pharmaceutical Company today announced that a marketing authorisation application (MAA) has been submitted to the European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active Ulcerative Colitis (UC) and Crohn's disease (CD), the two most common types of inflammatory bowel disease (IBD).


Nycomed Pharma Ltda.

Rodovia SP 340 Km 133,5

13 800 000 Jaguariuna



+55 19 3847 5526 +55 19 3867 4205
Nycomed Austria GmbH

St. Peter-Straße 25

4020 Linz



+43 70 6919 46 93 +43 732 65 53 09

Nycomed Christiaens SCA/CNA

Chaussée de Gand, 615

1080 Brussels



+32 2464 0630 +32 2464 0699

Oy Leiras Finland Ab

Teollisuuskatu 8

10601 Tammisaari



+358 20 746 5221 +358 20 76 5230
Germany, Oranienburg

Nycomed GmbH

Lehnitzstraße 70-98

16515 Oranienburg



+49 3301 818 275 +49 3301 818 360
Germany, Singen

Nycomed GmbH

Robert-Bosch-Straße 8

78224 Singen



+49 7531 84 1520 +49 7531 84 91520
Global Contract Manufacturing

Dybendal Alle 10

2630 Taastrup



+45 4677 1111 Global Contract Manufacturing www.takeda.com

Nycomed Pharma Sp. z.o.o.

Ul. Ksiestwa Lowickiego 12

99-420 Lyszkowice



+48 46 83 09 210 +48 46 83 09 400

Nycomed Elverum

2418 Elverum



+47 6242 83200 +47 6242 8399

Nycomed México S.A. de C.V.

Av. 1° de Mayo No 130 Col. Industrial Atoto

Naucalpan Edo. Mex

Naucalpan de Juarez



+52 55 53 87 9357 +52 55 53 58 1084